Alto Neuroscience (NYSE:ANRO) Releases Earnings Results, Beats Estimates By $0.05 EPS

Alto Neuroscience (NYSE:ANRO) released its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded up $0.08 during midday trading on Thursday, reaching $4.61. The company’s stock had a trading volume of 529,519 shares, compared to its average volume of 375,478. Alto Neuroscience has a one year low of $3.61 and a one year high of $24.00. The company has a 50 day moving average price of $10.02 and a 200 day moving average price of $11.46. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04.

Analyst Ratings Changes

Several research firms recently commented on ANRO. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus dropped their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.